Please assess the completion status of the following clinical trial:

Trial Title: Remicade in the Treatment of Patients With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The patients had to fulfill the following four inclusion criteria:~(I) Age between 18 and 60 years, (II) proven diagnosis according to the modified New York criteria 12 for definitive AS, (III) active disease with Bath AS Disease Activity Index (BASDAI) score above 4 and (IV) current or previous treatment with conventional non-steroidal anti-inflammatory drugs (NSAID) in adequate doses without sufficient effect.~Exclusion Criteria:~* current signs or symptoms of severe, progressive or uncontrolled hepatic, hematological, pulmonary, cardiac, neurological or cerebral disease;~* ongoing or past serious infection (including HIV and past or current tuberculosis);~* pregnancy or breast feeding;~* current malignancy or history of malignancy within the past five years;~* congestive heart failure and any contraindication to MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: None): Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).